ArticleOral oncology2014
Tailored immunotherapy for HPV positive head and neck squamous cell cancer.
Article in Oral oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 33 citations in OpenAlex.
- Human Papillomavirus: Update in Bridging Basic Science to Clinical and Public Health Innovations.Health science reports · 2026Article
- Immunotherapy for HPV Malignancies.Seminars in radiation oncology · 2021Review
- Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.Oral oncology · 2017Review
- The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.Annals of translational medicine · 2016Review
- HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management.Annual review of medicine · 2016Review
- Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Review
- Emerging biomarkers in head and neck cancer in the era of genomics.Nature reviews. Clinical oncology · 2015Review
- Acceler-dated fractionation: the end of the era of the large, "one size fits all" trial for locally advanced head and neck cancer.International journal of radiation oncology, biology, physics · 2014Article
- Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Human papilloma virus (HPV) associated oropharynx carcinoma (OPC) is increasingly common, with a distinct biology from HPV negative OPC. In spite of this better prognosis, morbidity is significant and treatment related after effects can be debilitating. Because the foreign viral proteins that drive HPV+ cancers are known, there are multiple options for tailored immune therapies. Herein we review the immunologic basis for disease and emerging immune therapies. The oncogenesis of HPV+ SCCHN goes beyond cell cycle deregulation, and relies on the immune escape through (E5, E6, and E7) downregulating antigen processing, interferon response, as well as STAT-1 signaling. Individual susceptibilities to HPV infection may vary. The treatment of HPV+ cancers has had a wide range of successes and failures. Perhaps the shining example of immunoprevention has been the L1 protein vaccines developed for cervical cancer prevention, however this vaccine has not been beneficial for people already infected. Therefore multiple strategies have been employed in the cancer therapeutic realm for people with existing disease. These agents range from peptides, to viral vectors, to adoptive cell therapy. In this review we consider the work done in both SCCHN and cervical cancer, as these therapeutic targets are the similar. The listed studies are not exhaustive, but rather illustrate experimental design and approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.